SJS Investment Consulting
DRUG icon

SJS Investment Consulting’s Bright Minds Biosciences DRUG Stock Holding History

SJS Investment Consulting’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$798 Buy
16
+11
+220% +$777 ﹤0.01% 2600
2026
Q2 		$351 Buy
+5
New +$393 ﹤0.01% 2362

Other funds holding DRUG

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SJS Investment Consulting's DRUG Position: Q3 2026 in Review

SJS Investment Consulting increased its Bright Minds Biosciences (DRUG) stake by 220% in Q3 2026, buying an estimated $777 and bringing the position to 16 shares worth $798. The position accounts for ﹤0.01% of the portfolio, ranked #2600.

SJS Investment Consulting first reported a position in DRUG in Q2 2026 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

  • SJS Investment Consulting held 16 shares of Bright Minds Biosciences worth $798 as of Q3 2026.
  • SJS Investment Consulting bought 11 Bright Minds Biosciences shares in Q3 2026, an estimated $777.
  • Bright Minds Biosciences made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2600 holding.
  • SJS Investment Consulting first reported a position in Bright Minds Biosciences in Q2 2026 and has held it in 2 quarters since.
  • 41 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.